Capricor Therapeutics (CAPR) Is Up 62.6% After Mounting Deramiocel FDA Scrutiny And Lawsuits - What's Changed

RegulatoryDeramiocelPositive

AI Analysis

Summary

Capricor Therapeutics stock rose 62.6% following FDA scrutiny of its Deramiocel drug candidate and ongoing lawsuits. The article title indicates regulatory challenges and legal issues affecting the company.

Importance:4/10

Sentiment:

0.30

FDA scrutinylitigationstock movement

Related Companies

$CAPR

Read the original article

Published by yahoo_finance on August 15, 2026 10:10 AM

Read Original